CompletedNot Applicable

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

France163 participantsStarted 2021-03-05

Plain-language summary

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with rheumatoid arthritis or spondyloarthritis * With positive serology for SARS-CoV-2 infection less than 3 months old at the time of inclusion * Under biotherapy, or conventional synthetic Disease-modifying antirheumatic drugs (csDMARD) or Nonsteroidal anti-inflammatory drugs (NSAIDs) or steroids for at least one month during the year 2020 * Agreeement to participate two years in the study Exclusion Criteria: * Pregnant or breastfeeding woman * Refusal to participate in the study

What they're measuring

Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres in patients with chronic inflammatory rheumatisms

Timeframe: at baseline

Distribution of anti-SARS-CoV-2 neutralising immunoglobulin titres in patients with chronic inflammatory rheumatisms

Timeframe: at 6 months after inclusion

Trial details

NCT IDNCT04530682

SponsorUniversity Hospital, Montpellier

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-06-23

View on ClinicalTrials.gov More Chronic Inflammatory Rheumatism trials